Comparing the outcomes of the present study with our previous studies using either HAGE- or WT1-ImmunoBody® vaccination programme as a monotherapy (data not shown), the combined HAGE/WT1 ImmunoBody® vaccines used herein were found to further improve the delay in the tumour growth in pre-immunised mice, but also and importantly, to delay tumour growth in a significant proportion of mice even when the vaccines were used after tumour implantation. The gene discussed is WT1; the disease is neoplasm.